Business
Adhera Therapeutics' DyrctAxessTM Platform Helps 78% of Patients Adhere to PRESTALIA(R); Achieves Exceptionally High Level of Drug Adherence to an Antihypertensive Medication
Adhera Therapeutics' DyrctAxessTM Platform Helps 78% of Patients Adhere to PRESTALIA(R); Achieves Exceptionally High Level of Drug Adherence to an Antihypertensive Medication.
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"Over 200 prescribers have written at least one prescription for PRESTALIA and over 600 patients are taking the medicationPRESTALIA was launched in Q3 2018, powered by the Company's proprietary DyrctAxess platform RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / February 6, 2019 / Adhera Therapeutics, Inc. (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, announced today that its proprietary DyrctAxess Technology Platform has helped 78% of patients adhere to PRESTALIA. In doing so, the Company has achieved an exceptional level of drug adherence to an antihypertensive medication. Additionally, over 200 prescribers have written at least one prescription for PRESTALIA, and over 600 patients are taking the medication. Adhera Therapeutics launched sales of PRESTALIA in the third quarter of 2018, powered by its DyrctAxess technology platform. PRESTALIA is licensed to Adhera by Servier, an international pharmaceutical company. Robert Moscato, Jr., CEO of Adhera Therapeutics, commented, ''Our mission at Adhera Therapeutics is to build an integrated pharmaceutical company that creates value by achieving an unprecedented level of drug adherence. We are pleased to be executing against that goal, as demonstrated by DyrctAxess' 78% adherence rate for our first drug, PRESTALIA.'' Drug adherence is a substantial concern, especially in hypertension. The World Health Organization has estimated half of the patients prescribed an antihypertensive drug stop taking it within 1 year. Whereas persistence with antihypertensive treatment significantly reduces long-term cardiovascular risk. Pierre Gaillard, MD, Head of Global Marketing & Market Access of Servier stated, ''We are pleased to be working with Adhera, which shares with Servier the ambition to put patient needs at the heart of all our actions. Servier, as a leading company in Hypertension, has developed a very comprehensive portfolio adapted to the different patients profiles and their specific needs. PRESTALIA brings an innovative way to treat newly diagnosed hypertensive patients in one single pill. We are excited to continue to develop the partnership with Adhera, and together bring new innovative solutions for hypertensive patients.'' Mr. Moscato added, ''We are pleased to partner with Servier. Announcements ...